ORIC Pharmaceuticals Inc (STU:4TZ)
€ 9.4 0.2 (2.17%) Market Cap: 670.50 Mil Enterprise Value: 407.74 Mil PE Ratio: 0 PB Ratio: 2.30 GF Score: 42/100

Oric Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2021 / 01:45PM GMT
Release Date Price: €20.2 (+2.02%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel entitled Aiming for the Bull's Eye - Latest Advances in Targeted Oncology, and it's my great pleasure to have with me 4 distinguished expert speakers from IDEAYA Biosciences, Yujiro Hata, who is the CEO; from ORIC Pharmaceuticals, Jacob Chacko, also CEO; from Rain Therapeutics, Avanish Vellanki, Chairman and CEO; and last but not least, from Syndax Pharmaceuticals, Briggs Morrison, also CEO of the company. So welcome, gentlemen. Thank you very, very much for participating.

As a starting point, I think it would be great for those listeners less familiar with each of your pipelines for each of you to go through and just give a brief 2 to 3-minute overview of your company and the pipeline to level set the discussion. So, Avanish, you want to kick it off?

Avanish Vellanki
Rain Therapeutics Inc. - Co-Founder, CEO & Chairman

Sure. Happy to. And, Yigal, thanks for having

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot